This site is only for UK healthcare professionals and contains promotional information.

speciality

This page is in development

This page is in development, please come back again soon!

almirall mantenimiento

IE-NOP-2400008 June 2024

Sites of interest

Almirall.co.uk

UK-EBG-2400076 September 2024

UK-Adverse events should be reported. Reporting forms and information can be found at MHRA https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Almirall Ltd. Tel. 0800 0087 399.

IE-Adverse events should be reported. Reporting forms and information can be found at HPRA Pharmacovigilance, Website: www.hpra.ie. Adverse events should also be reported to Almirall Ltd. Tel. +353 (0) 1431 9836

Prescribing Information

Ebglyss®▼ (lebrikizumab)

ILUMETRI® (tildrakizumab)

Klisyri®▼ (tirbanibulin)

Skilarence® (dimethyl fumarate)

Wynzora® (calcipotriol and betamethasone dipropionate)

©2021 Almirall

This is a promotional website intended for UK healthcare professionals only (HCPs). Please confirm you are a healthcare professional before accesing the content.

I am a healthcare professional
I am not a healthcare professional

Leaving AlmirallMED

Dear user,

You are leaving the website www.almirallmed.co.uk Specific policies may apply on the new website you are visiting, all interactions with that website are your sole responsibility.

Stay
Leave